journal article·2026-06Open access

Artificial intelligence-assisted lipid nanoparticles formulation in drug delivery for precision therapy

Chao Huang, Weimin Zuo, Jing Xiao, Chan Xiong, Lifeng Zhu, Yanhong Su, Meixiao Zhan

Abstract

Lipid nanoparticles (LNPs) have emerged as significant drug delivery carriers due to their excellent biocompatibility and high drug-loading capacity. Traditional LNP development, however, relies heavily on costly and time-consuming experimental approaches. Recently, artificial intelligence (AI), particularly machine learning, has advanced nanomedicine development by enabling more efficient data-driven formulation strategies. By leveraging high-dimensional experimental datasets, AI can optimize formulations as well as predict physicochemical properties, in vitro and in vivo behaviors, and therapeutic efficacy, thereby significantly reducing development timelines. This review highlights recent advances in AI technologies and their potential for reshaping the development process of LNPs with high delivery efficiency. Firstly, this review outlines the core physicochemical properties widely used in AI-assisted LNP development. Next, AI tools, techniques, and the rationale behind selecting specific techniques for NP development are elucidated. Subsequently, the critical role of AI in LNP development is also discussed, highlighting its contribution to formulation design, property prediction, biological analysis, and efficacy evaluation. Finally, current challenges and the future opportunities for AI in advancing precision drug delivery are discussed, providing a foundation for building the rational and efficient LNP design to support personalized precision therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Nanoparticle-Based Drug Delivery · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Efficient delivery of lomitapide using hybrid membrane-coated tetrahedral DNA nanostructures for glioblastoma therapy
3. Advantages of nanomedicine in cancer therapy: a review10.1021/acsanm.3c04487 ↗
4. Progress, challenges, and future of nanomedicine10.1016/j.nantod.2020.101008 ↗
5. Clinical translation of nanomedicines for brain diseases: current challenges and future directions10.1016/j.jconrel.2025.114426 ↗
6. Lipid nanoparticles for targeted delivery of anticancer therapeutics: recent advances in development of siRNA and lipoprotein-mimicking nanocarriers10.1016/j.addr.2023.115136 ↗
7. Mobilizing STING pathway via a cationic liposome to enhance doxorubicin‐induced antitumor immunity
8. A dual-targeting liposome enhances triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation
9. Liposomal enzyme nanoreactors based on nanoconfinement for efficient antitumor therapy
10. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement10.1021/acsnano.1c04996 ↗
11. Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment10.1016/j.jconrel.2021.11.006 ↗
12. Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment10.1016/j.cis.2023.102871 ↗
13. Cationic lipids‐mediated dual‐targeting of both dendritic cells and tumor cells for potent cancer immunotherapy
14. Lipid nanoparticle-assisted mRNA therapy for cancer treatment10.1063/5.0247029 ↗
15. Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA10.1186/s12951-024-02812-x ↗
16. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity10.1016/j.jconrel.2021.05.021 ↗
17. Glucose-responsive charge-switchable lipid nanoparticles for insulin delivery
18. Revolutionizing drug formulation development: the increasing impact of machine learning10.1016/j.addr.2023.115108 ↗
19. Review of machine learning for lipid nanoparticle formulation and process development10.1016/j.xphs.2024.09.015 ↗
20. Machine learning in preclinical drug discovery10.1038/s41589-024-01679-1 ↗
21. Estimated research and development investment needed to bring a new medicine to market, 2009-201810.1001/jama.2020.1166 ↗
22. Why 90% of clinical drug development fails and how to improve it?10.1016/j.apsb.2022.02.002 ↗
23. Development of in silico methodology for siRNA lipid nanoparticle formulations10.1016/j.cej.2022.136310 ↗
24. A deep learning approach to antibiotic discovery10.1016/j.cell.2020.01.021 ↗
25. Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases10.1016/j.addr.2021.113922 ↗
26. Preclinical-to-clinical anti-cancer drug response prediction and biomarker identification using TINDL10.1016/j.gpb.2023.01.006 ↗
27. CCPred: global and population-specific colorectal cancer prediction and metagenomic biomarker identification at different molecular levels using machine learning techniques10.1016/j.compbiomed.2024.109098 ↗
28. Combinatorial discovery of antibacterials via a feature-fusion based machine learning workflow10.1039/D3SC06441G ↗
29. Bridging machine learning and peptide design for cancer treatment: a comprehensive review10.1007/s10462-025-11148-3 ↗
30. Integrated in silico formulation design of self-emulsifying drug delivery systems10.1016/j.apsb.2021.04.017 ↗
31. In silico formulation prediction of drug/cyclodextrin/polymer ternary complexes by machine learning and molecular modeling techniques10.1016/j.carbpol.2021.118712 ↗
32. Rational design of safer inorganic nanoparticles via mechanistic modeling-informed machine learning10.1021/acsnano.5c03590 ↗
33. The role of machine learning in predicting titanium dioxide nanoparticles induced pulmonary pathology using transcriptomic biomarkers10.1016/j.jhazmat.2025.138240 ↗
34. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures10.1136/jitc-2023-006788 ↗
35. Merging data curation and machine learning to improve nanomedicines10.1016/j.addr.2022.114172 ↗
36. Prediction of oral pharmacokinetics using a combination of in silico descriptors and in vitro ADME properties10.1021/acs.molpharmaceut.0c01009 ↗
37. Artificial intelligence for drug discovery: are we there yet?10.1146/annurev-pharmtox-040323-040828 ↗
38. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models10.1038/s41587-024-02143-0 ↗
39. Toward the integration of machine learning and molecular modeling for designing drug delivery nanocarriers10.1002/adma.202407793 ↗
40. Prediction and design of nanozymes using explainable machine learning10.1002/adma.202201736 ↗
41. Application of machine learning techniques to the analysis and prediction of drug pharmacokinetics10.1016/j.jconrel.2022.11.014 ↗
42. Machine learning instructed microfluidic synthesis of curcumin-loaded liposomes10.1007/s10544-023-00671-1 ↗
43. Comparative study of lipid nanoparticle-based mRNA vaccine bioprocess with machine learning and combinatorial artificial neural network-design of experiment approach10.1016/j.ijpharm.2023.123012 ↗
44. Sorting hidden patterns in nanoparticle performance for glioblastoma using machine learning algorithms10.1016/j.ijpharm.2020.120095 ↗
45. Rational design of lipid nanoparticles for enhanced mRNA vaccine delivery via machine learning
46. Understanding intracellular biology to improve mRNA delivery by lipid nanoparticles10.1002/smtd.202201695 ↗
47. Integrative machine learning model of RNA modifications predict prognosis and treatment response in patients with breast cancer10.1186/s12935-025-03651-y ↗
48. Artificial intelligence aids in development of nanomedicines for cancer management10.1016/j.semcancer.2023.01.005 ↗
49. In silico insights into the membrane disruption induced by the protonation of ionizable lipids10.1007/s00894-025-06308-9 ↗
50. The role of protein-lipid interactions in priming the bacterial translocon10.3390/membranes14120249 ↗
51. CHARMM-GUI supports the amber force fields10.1063/5.0012280 ↗
52. 3rd, pyCHARMM: embedding CHARMM functionality in a python framework10.1021/acs.jctc.3c00364 ↗
53. Insights into lipid-protein interactions from computer simulations10.1007/s12551-021-00876-9 ↗
54. Proteomic blood profiles obtained by totally blind biological clustering in stable and exacerbated COPD patients10.3390/cells13100866 ↗
55. Raschka · 2022
56. How to perform a meta-analysis: a practical step-by-step guide using R software and RStudio
57. Survey: tensorflow in machine learning10.1088/1742-6596/2273/1/012008 ↗
58. Conventional machine learning and deep learning in Alzheimer's disease diagnosis using neuroimaging: a review10.3389/fncom.2023.1038636 ↗
59. Transfer learning: a friendly introduction10.1186/s40537-022-00652-w ↗
60. Ensemble learning for disease prediction: a review10.3390/healthcare11121808 ↗
61. The role of lipid components in lipid nanoparticles for vaccines and gene therapy10.1016/j.addr.2022.114416 ↗
62. Liposomes as biocompatible and smart delivery systems - the current state10.1016/j.cis.2022.102757 ↗
63. Near-infrared light-responsive liposomes for protein delivery: towards bleeding-free photothermally-assisted thrombolysis10.1016/j.jconrel.2021.07.024 ↗
64. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells10.1186/s12951-020-00604-7 ↗
65. Pectin co-functionalized dual layered solid lipid nanoparticle made by soluble curcumin for the targeted potential treatment of colorectal cancer10.1016/j.carbpol.2020.117180 ↗
66. Solid lipid nanoparticles for hydrophilic drugs10.1016/j.jconrel.2021.05.032 ↗
67. Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review10.3390/pharmaceutics15061593 ↗
68. Nanostructured lipid carriers for delivery of chemotherapeutics: a review10.3390/pharmaceutics12030288 ↗
69. Advances in nanostructured lipid carriers for colorectal cancer treatment: a comprehensive review10.2174/0115672018340391250321041056 ↗
70. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components10.1021/acs.molpharmaceut.1c00916 ↗
71. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy10.1016/j.jconrel.2024.06.023 ↗
72. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)10.1039/D1BM01454D ↗
73. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy10.1002/adma.202303261 ↗
74. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA10.1038/s41467-020-14527-2 ↗
75. Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles10.1021/acsnano.0c10064 ↗
76. Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy10.1021/acsami.8b22693 ↗
77. Targeted liposomal drug delivery: a nanoscience and biophysical perspective10.1039/D0NH00605J ↗
78. Beyond the EPR effect: intravital microscopy analysis of nanoparticle drug delivery to tumors10.1016/j.addr.2025.115550 ↗
79. Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors
80. Regulating size and charge of liposomes in microneedles to enhance intracellular drug delivery efficiency in skin for psoriasis therapy10.1002/adhm.202302314 ↗
81. The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution10.1021/acs.molpharmaceut.9b01182 ↗
82. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs10.1016/j.jconrel.2022.03.046 ↗
83. Mesenchymal stem cell membrane-camouflaged liposomes for biomimetic delivery of cyclosporine a for hepatic ischemia-reperfusion injury prevention
84. Manufacturing process of liposomal formation: a coarse-grained molecular dynamics simulation10.1016/j.ijpharm.2024.124288 ↗
85. Lipid and transcriptional regulation in a Parkinson's disease mouse model by intranasal vesicular and hexosomal plasmalogen-based nanomedicines10.1002/adhm.202470093 ↗
86. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects10.1073/pnas.2309472120 ↗
87. Rational design of unsaturated, thioether ionizable lipids for enhanced in vivo mRNA delivery10.1002/adhm.202501037 ↗
88. Optimizing the modification density of acid oligopeptides to enhance the bone-targeting activity of liposomes10.1016/j.compositesb.2022.110288 ↗
89. Dual-responsive nanoparticles with transformable shape and reversible charge for amplified chemo-photodynamic therapy of breast cancer10.1016/j.apsb.2022.03.010 ↗
90. Impact of physicochemical properties on biological effects of lipid nanoparticles: are they completely safe10.1016/j.scitotenv.2024.172240 ↗
91. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-cas gene editing10.1038/s41563-020-00886-0 ↗
92. Influencing factors and strategies of enhancing nanoparticles into tumors in vivo10.1016/j.apsb.2021.03.033 ↗
93. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine10.1021/acsnano.2c04543 ↗
94. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement10.1016/j.jconrel.2021.11.042 ↗
95. To PEGylate or not to PEGylate: immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives10.1016/j.addr.2021.114079 ↗
96. A nanomedicine structure-activity framework for research, development, and regulation of future cancer therapies10.1021/acsnano.2c06337 ↗
97. Lipid nanoparticles optimized for targeting and release of nucleic acid
98. Lipid nanoparticles for nucleic acid delivery: current perspectives10.1016/j.addr.2020.06.002 ↗
99. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors10.1016/j.jconrel.2023.03.016 ↗
100. CAR T cells produced in vivo to treat cardiac injury10.1126/science.abm0594 ↗